

# Exploring the Landscape of Optic Neuropathy and Vasculopathy: the LOVE study

<b>Submission date</b> 26/03/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 03/04/2024	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/04/2024	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Diabetic retinopathy neuropathy (DRN) is the term used to describe the initial degeneration of nerve cells in the retina (the light-sensitive tissue at the back of the eye) due to elevated levels of blood sugar. However, the precise mechanism behind this condition remains unclear. This study seeks to investigate how DRN progresses by using various imaging techniques to examine the eye.

### Who can participate?

Individuals aged 18 years and older with and without diabetes who live in Guangzhou, China

### What does the study involve?

Comprehensive eye and general tests are performed every 2 years over a period of 4 years. Participants receive comprehensive eye and general tests and one-on-one ophthalmologist consultations based on the exam results. All the exams follow the normal clinical operation.

### What are the possible benefits and risks of participating?

Participants benefit from receiving comprehensive eye and general tests and one-on-one ophthalmologist consultations based on the results. No additional risks are anticipated as all the exams follow the normal clinical operation.

### Where is the study run from?

Zhongshan Ophthalmic Center, Sun Yat-sen University (China)

### When is the study starting and how long is it expected to run for?

December 2023 to December 2027

### Who is funding the study?

Science and Technology Projects in Guangzhou (China)

### Who is the main contact?

Dr Wei Wang, wangwei@gzzoc.com

# Contact information

## Type(s)

Public, Scientific, Principal Investigator

## Contact name

Dr Wei Wang

## Contact details

No. 54 Xianlie Nan Road

Yuexiu District

Guangzhou

China

510060

+86 (0)20 87334687

wangwei@gzzoc.com

# Additional identifiers

## EudraCT/CTIS number

Nil known

## IRAS number

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

LOVE-2024-v1

# Study information

## Scientific Title

Landscape of optic neuropathy and vasculopathy evolution (LOVE) study

## Acronym

LOVE

## Study objectives

To explore the longitudinal trajectory and key metabolic markers of diabetic optic neurodegeneration based on large population cohorts and multimodal ocular imaging in vivo

## Ethics approval required

Ethics approval required

## Ethics approval(s)

Approved 08/01/2024, Zhongshan Ophthalmic Center Ethics Committee of Sun Yat-sen University (No. 7 Jinsui Road, Zhujiang New Town, Guangzhou, 510060, China; +86 (0)20 87332529; zocethics@163.com), ref: 2024KYPJ003

**Study design**

Retrospective and prospective ambispective cohort study

**Primary study design**

Observational

**Secondary study design**

Cohort study

**Study setting(s)**

Hospital

**Study type(s)**

Screening

**Participant information sheet****Health condition(s) or problem(s) studied**

Optic neuropathy in individuals with diabetes

**Interventions**

The LOVE study is a retrospective and prospective ambispective cohort study, including individuals with and without diabetes who attend Zhongshan Ophthalmic Center (ZOC) screening. All individuals in this study will be followed up every 2 years over a continuous period of 4 years. The examinations include questionnaire surveys, general physical examinations, blood sample collection, regular ocular examinations (such as intraocular pressure, refraction), (ultra-widefield) optical coherence tomography (OCT), ultra-widefield OCT angiography (OCTA), and (ultra-widefield) fundus photography.

**Intervention Type**

Other

**Primary outcome measure**

Longitudinal change of peripapillary retinal nerve fiber layer thickness measured using optical coherence tomography (OCT) in eligible participants at baseline and each follow-up visit (2 and 4 years)

**Secondary outcome measures**

1. Longitudinal change of macular ganglion cell-inner plexiform layer (GCIPL) thickness measured using optical coherence tomography (OCT) in eligible participants at baseline and each follow-up visit (2 and 4 years)
2. Longitudinal change of macular ganglion cell complex (GCC) thickness measured using OCT in eligible participants at baseline and each follow-up visit (2 and 4 years)
3. Longitudinal change of macular microcirculation measured using optical coherence tomography angiography (OCTA) in eligible participants at baseline and each follow-up visit (2 and 4 years)
4. Longitudinal change of microcirculation in optic nerve head measured using OCTA in eligible participants at baseline and each follow-up visit (2 and 4 years)

**Overall study start date**

30/12/2023

**Completion date**

30/12/2027

## Eligibility

**Key inclusion criteria**

1. Community-registered patients with diabetes
2. Individuals who live in Guangzhou for more than 6 months
3. Aged 18 years and older
4. Individuals who are capable of cooperating with ocular examinations and meeting quality standards
5. Individuals who voluntarily participate in this study
6. Individuals who do not participate in other trials or treatments aimed at preventing or delaying the onset and progression of diabetic retinopathy (DR)
7. Absence of retinal lesions, or retinal/macular lesions not meeting the positive criteria for referable DR

**Participant type(s)**

Patient

**Age group**

Mixed

**Lower age limit**

18 Years

**Upper age limit**

100 Years

**Sex**

Both

**Target number of participants**

1200

**Key exclusion criteria**

1. Individuals who cannot cooperate with examinations

**Date of first enrolment**

01/01/2017

**Date of final enrolment**

30/12/2024

## Locations

**Countries of recruitment**

China

**Study participating centre**  
**Zhongshan Ophthalmic Center, Sun Yat-sen University**  
No. 54 Xianlie Nan Road  
Yuxiu District  
Guangzhou  
China  
510060

## **Sponsor information**

**Organisation**  
National Sun Yat-sen University

**Sponsor details**  
Zhongshan Ophthalmic Center  
No. 54. Xianlie Nan Road  
Yuxiu District  
Guangzhou  
China  
China  
+86 (0)20 87330487  
wangw289@mail.sysu.edu.cn

**Sponsor type**  
University/education

**Website**  
<http://www.nsysu.edu.tw/bin/home.php?Lang=en>

**ROR**  
<https://ror.org/00mjawt10>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**  
Science and Technology Projects in Guangzhou (China)

# Results and Publications

## Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

## Intention to publish date

30/12/2026

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Dr Wei Wang (wangwei@gzzoc.com). Informed consent will be obtained before the participant joins the study. The study will follow the legal restrictions of the Ethics Committee of Zhongshan Ophthalmic Center, Sun Yat-sen University. For access to the data, please contact the principal investigator after the study is completed.

## IPD sharing plan summary

Available on request